Brussels, Belgium

Silvia Lovera


 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Silvia Lovera: Innovator in CNS Disorder Treatments

Introduction

Silvia Lovera is a prominent inventor based in Brussels, Belgium. She has made significant contributions to the field of neuroscience, particularly in the development of treatments for central nervous system (CNS) disorders. Her innovative work has led to the creation of a patent that addresses critical health issues.

Latest Patents

Silvia Lovera holds a patent for N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis. This patent discloses N-(phenyl)-1H-indole-3-sulfonamide and N-(phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide derivatives, which are substituted at the 1- and 6-positions of the respective moieties. The compounds exhibit GPR17 modulating properties that are beneficial for treating or preventing various CNS diseases, particularly myelinating disorders like multiple sclerosis.

Career Highlights

Silvia Lovera is currently associated with UCB Pharma GmbH, where she continues her research and development efforts. Her work is characterized by a commitment to advancing medical science and improving patient outcomes through innovative therapies.

Collaborations

Silvia has collaborated with notable colleagues, including Cécile Pegurier and Christa E. Mueller. These partnerships have enhanced her research capabilities and contributed to the success of her projects.

Conclusion

Silvia Lovera's contributions to the field of CNS disorders through her innovative patents and collaborations highlight her role as a leading inventor in medical research. Her work continues to pave the way for new treatments that can significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…